Navigation Links
New hope for hormone resistant breast cancer
Date:7/22/2013

A new finding provides fresh hope for the millions of women worldwide with oestrogen receptor positive breast cancer. Australian scientists have shown that a specific change, which occurs when tumours become resistant to anti-oestrogen therapy, might make the cancers susceptible to treatment with chemotherapy drugs.

Seventy percent of breast cancer patients have oestrogen receptor positive cancer, and most patients respond well to anti-oestrogen therapies, for a few years at least. Within 15 years, however, 50% will relapse and eventually die from the disease.

Dr Andrew Stone, Professor Susan Clark and Professor Liz Musgrove, from Sydney's Garvan Institute of Medical Research, in collaboration with scientists from Cardiff University, have demonstrated that the BCL-2 gene becomes epigenetically 'silenced' in resistant tumours. This process is potentially detectable in the blood, providing a diagnostic marker. Their findings are now online in the international journal Molecular Cancer Therapetics.

Epigenetics involves biochemical changes in our cells that directly impact our DNA, making some genes active, while silencing others. Epigenetic events include DNA methylation, when a methyl group - one carbon atom and three hydrogen atoms - attaches to a gene, determining the extent to which it is 'switched on' or 'switched off'.

Dr Stone and colleagues have shown in human disease, as well as in several different cell models, that BCL-2 is silenced in oestrogen-resistant tumours by DNA methylation.

"The main purpose of the BCL-2 gene is to keep cells alive, so when the gene is silenced, cells become more vulnerable to chemotherapy," said Dr Stone.

"The next step will be to test our findings in clinical studies. We propose that if the BCL-2 gene is silenced, patients with oestrogen receptor positive breast cancer would benefit from combination therapy. In other words, tamoxifen could be used in combination with a chemotherapy drug, to kill off vulnerable tumour cells."

"Excitingly, this is something that could be implemented into clinical practice very quickly, since the technology now exists to profile methylation of BCL-2 in all patients both oestrogen responsive and oestrogen resistant patients. In addition, the proposed chemotherapy drugs are already in use."

"If such a test were to be implemented, we believe it could help patients much earlier hopefully shutting down tumours at an early stage."


'/>"/>

Contact: Alison Heather
a.heather@garvan.org.au
61-292-958-128
Garvan Institute of Medical Research
Source:Eurekalert

Related medicine news :

1. Study links cardiac hormone-related inflammatory pathway with tumor growth
2. Osteoporosis drug may help treat advanced hormone-sensitive breast cancer
3. Hormones for Digestion and Weight Loss Article and Video Published by BetterDigestion.org
4. The Gluten Free Society Launches Hormone Awareness Campaign
5. Hormone replacement therapy -- clarity at last!
6. XRMD: Beyond AREDS2: Vision Improvement using Hormones, Genetics, Methylation, Nutrition and Anti-Oxidative Therapy
7. Bioidentical Hormones Offer Natural Solution for Hormone Imbalance in Menopausal Women; Now Available at Women's Excellence in Menopause near Auburn Hills, Michigan
8. New HGH.com Web Site - Purchasing Human Growth Hormone and Bodybuilding Supplements Just Got Easier
9. Women's Excellence in Menopause Now Offering Treatment Options for Decreased Sex Drive near Rochester Hills, Michigan; Natural Therapy Available via Bioidentical Hormones
10. New Article and Video Describe How Hormones Help Lose Weight Published by BetterDigestion.org
11. Hormone Shows Potential as Diabetes Treatment in Mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... 23, 2017 , ... The American Academy of Thermology ... development, healthcare training and clinical application of medical infrared imaging, has announced the ... Qualification Courses for Technicians, respectively. , For the first time the AAT is ...
(Date:1/23/2017)... Oregon (PRWEB) , ... January 23, 2017 , ... ... announced today it has earned organic certification under the USDA National Organic Program ... USDA Organic Certification process, we have established organic production and handling systems to ...
(Date:1/23/2017)... Georgia (PRWEB) , ... January 23, 2017 , ... ... in providing high-quality general gynecological care and gynecological services for women ... providing personalized care for a wide variety of reproductive services from routine health ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Life Under Blankets”: an ... an early age. “Life Under Blankets” is the creation of published author, Kimberly Mitchell, ... Campus in Chicago. She went on to pursue a master’s degree in education in ...
(Date:1/22/2017)... ... January 22, 2017 , ... Zifam Pinnacle, an Australian company dedicated to providing ... big-name retail buyers at the January ECRM Trade Show in Hilton Head, SC. , ... safety standards in all of its creations to help create a more traditional and ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... , January 23, 2017 Ahead of ... to see how they have fared at the close: Kite Pharma ... Inc. (NASDAQ: OVAS ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... Biotechnology shares were relative laggards on Friday, January 20 th , ... our complimentary research reports on these stocks now at: ...
(Date:1/23/2017)... SAN DIEGO , 23 janvier 2017  ResMed ... Winter Haven , Floride) ont annoncé aujourd,hui qu,ils se ... les litiges existants entre les parties. BMC et 3B ... de paiements de droits à ResMed, et ResMed effectuera ... à 3B pour clore le litige de Floride entre ...
(Date:1/23/2017)... Jan. 23, 2017 Just two weeks remain until legal experts ... gather in Central London to discuss the flow ... in the market, Parallel Trade 2017 . In the ... of attendees which is available to read in the event download ... Some of ...
Breaking Medicine Technology: